EP
FSTX

Eversept Partners’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Eversept Partners’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-49,933
Closed -$251K – 113
2021
Q4 		$251K Hold
49,933
– – 0.02% 105
2021
Q3 		$366K Sell
49,933
-50,067
-50% -$344K 0.03% 103
2021
Q2 		$859K Buy
+100,000
New +$853K 0.06% 80

Other funds holding FSTX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Eversept Partners's FSTX Position: Q1 2022 in Review

Eversept Partners sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2022, closing a stake of 49,933 shares — an estimated $251K sold.

Eversept Partners first reported a position in FSTX in Q2 2021 and held it in 3 quarters. The position peaked at $859K in Q2 2021. 40 funds tracked by Wall St. Rank hold FSTX as of Q1 2022.

  • Eversept Partners reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Eversept Partners sold 49,933 F-star Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $251K.
  • Eversept Partners first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Eversept Partners's F-star Therapeutics, Inc. Common Stock position peaked at $859K in Q2 2021.
  • 40 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Eversept Partners's 13F filing for Q1 2022, filed 16 May 2022.